Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 7—July 2020
Dispatch

Clinical Characteristics of Patients Hospitalized with Coronavirus Disease, Thailand

Wannarat A. Pongpirul, Joshua A. Mott, Joseph V. WoodringComments to Author , Timothy M. Uyeki, John R. MacArthur, Apichart Vachiraphan, Pawita Suwanvattana, Sumonmal Uttayamakul, Supamit Chunsuttiwat, Tawee Chotpitayasunondh, Krit Pongpirul, and Wisit Prasithsirikul
Author affiliations: Bamrasnaradura Infectious Diseases Institute, Bangkok, Thailand (W.A. Pongpirul, A. Vachiraphan, P. Suwanvattana, S. Uttayamakul, W. Prasithsirikul); US Centers for Disease Control and Prevention–Thailand Ministry of Public Health Collaboration, Bangkok (J.A. Mott, J.V. Woodring, J.R. MacArthur); US Centers for Disease Control and Prevention, Atlanta, Georgia, USA (T.M. Uyeki); Thailand Ministry of Public Health, Bangkok (S. Chunsuttiwat); Queen Sirikit National Institute for Child Health, Bangkok (T. Chotpitayasunondh); Chulalongkorn University, Bangkok (K. Pongpirul)

Main Article

Table 1

Demographics, baseline characteristics, illness histories, laboratory values and treatment therapies of confirmed COVID-19 patients in Bamrasnaradura Infectious Diseases Institute, Bangkok, Thailand, 2020*

Demographics Patient no.
 Total, %
1 2 3 4 5 6 7 8 9 10† 11
Age, y/sex 61/F 74/F 68/M 66/F 57/F 34/M 61/M 63/M 28/F 51/M 49/M 55 M/45 F
Ethnicity CH CH CH CH CH CH CH CH CH TH TH 82 CH/18 TH
Occupation
 Ret
 Ret
 Ret
 Ret
 Ret
 EE
 Ret
 Ret
 Tour guide
 Taxi driver
 Officer
 54 Ret/46 other
Detected through airport screening Y Y Y N N N N N N N N 27 Y/73 N
Detected through contact tracing N N N Y N N N N N N N 9 Y/91 N
Detected after patient voluntarily sought medical care N N N N Y Y Y Y Y Y Y 64 Y/36 N
Visited Hunan Seafood Market
 N
 N
 N
 N
 N
 N
 N
 N
 N
 N
 N
 0
Underlying conditions
Diabetes N N N N N Y N N N Y N 18 Y/82 N
Hypertension Y Y N Y N N N N N Y N 36 Y/64 N
COPD N N N N N N N N N N N 0
Asthma N N N N N N N N N N N 0
Cancer N N N N N N N N N N N 0
Cardiovascular disease N Y N Y N N N Y N N N 27 Y/73 N
Cerebrovascular disease N N N N N N N Y N N N 9 Y/91 N
Chronic liver disease N N N N N N N N N N Y 9 Y/91 N
Any chronic condition
 Y
 Y
 N
 Y
 N
 Y
 N
 Y
 N
 Y
 Y
 64 Y/36 N
Current smoker N N N N N N N N N N N 0
Pregnant
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 NA
 N
 NA
 NA
 0
Laboratory values at time of admission (reference range)
Leukocytes ×109/L (4.5–8) 1.9↓ 3.3↓ 4 3.6 3.9 3.4↓ 5.8 4.1 4.9 5.8 2.5↓
Neutrophils, % (36–70) 48 64 66 63 56 80↑ 63 83 73↑ 58 54
Lymphocytes, % (23–57) 40 19↓ 25 25 33 1↓ 30 16↓ 23 31 30
Platelets ×106 /μL (140–400) 127↓ 16.4↓ 12.6↓ 177 167 169 168 18.4↓ 153 368 167
Hemoglobin, g/dL (11–14) 13.3 12.8 11.5 13.1 13.2 13.3 15.3↑ 13.8 11.4 14 14.8↑
Hematocrit, % (35–41) 38 38 33↓ 37 37.9 38 45↑ 39 34 41 43↑
ALT, U/L (0–31) 18 27 18 83↑ 23 16 22 22 24 24 26
AST, U/L (0–31)
 14
 12
 15
 47↑
 16
 19
 20
 14
 25
 16
 22
Other diagnostics
Oxygen saturation on room air at admission 98 97 95 98 99 99 98 99 96 91↓ 97
Results from Biofire-33 multiplex PCR‡
Haemophilus influenzae + + – – + + – – – – –
Adenovirus – + – – – – – – – – –
Influenza A – – – – – – + – – – –
Klebsiella pneumoniae
 –
 –
 –
 –
 –
 –
 –
 –
 –
 –
 +
Treatments
Antimicrobial drugs, dose
Ceftriaxone, 2 g 4×/d IV 1 0 7 0 0 0 7 0 0 7 0
Ceftriaxone, 2 g/d orally 0 7 0 0 0 0 0 0 0 0 0
AMOX/CLAV, 2 g 4×/d orally 6 0 0 0 0 0 0 0 0 0 7
Oseltamivir, 150 mg 4×/d orally 5 0 0 0 0 0 5 0 0 0 5
Nasal cannula, 5 L, no. days
 0
 0
 0
 0
 0
 0
 0
 0
 0
 3
 0
Duration of signs and symptoms reported at admission, d Median (IQR)/ mean (SD)
Cough 1 1 1 0 2 1 4 2 3 8 5 2 (1–4)/2.5 (2.3)
Malaise or fatigue 4 2 4 0 2 4 13 2 3 5 5 4 (2–5)/4.0 (3.3)
Fever 2 2 4 0 3 4 4 2 2 8 5 3 (2–4)/3.3 (2.1)
Sore throat 4 0 3 0 3 2 4 2 3 7 5 3 (2–4)/3.0 (2.0)
Rhinorrhea 2 2 4 0 2 1 3 2 2 2 4 2 (2–3)/2.2 (1.2)
Headache 1 0 2 0 0 0 0 2 1 5 3 1 (0–2)/1.3 (1.6)
Vomiting 0 1 1 0 0 0 0 1 0 0 0 0 (0–1)/0.3 (0.5)
Diarrhea 0 0 1 0 0 0 0 1 0 0 0 0/0.2 (0.4)

*ALT, alanine aminotransferase; AMOX/CLAV, amoxicillin/clavulanate; AST, aspartate aminotransferase; COVID-19, coronavirus disease; CH, Chinese; EE, electrical engineer; IV, intravenous; NA, not applicable; Ret, retired; TH, Thai; ↓, low; ↑, high; +, positive; –, negative.
†(2)
‡BioFire Diagnostics (https://www.biofiredx.com)

Main Article

References
  1. Department of Medical Sciences, Ministry of Public Health, Thailand. Diagnostic detection of novel coronavirus 2019 by real time RT-PCR. Version 0. 23 January 2020. [cited 2020 Feb 16] https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-for-detection-of-ncov-rirl-nat-inst-health-t.pdf?sfvrsn=42271c6d_4
  2. Pongpirul  WA, Pongpirul  K, Ratnarathon  AC, Prasithsirikul  W. Journey of a Thai taxi driver and novel coronavirus. N Engl J Med. 2020;382:1067–8. DOIPubMedGoogle Scholar
  3. Phan  LT, Nguyen  TV, Luong  QC, Nguyen  TV, Nguyen  HT, Le  HQ, et al. Importation and human-to-human transmission of a novel coronavirus in Vietnam. N Engl J Med. 2020;382:872–4. DOIPubMedGoogle Scholar
  4. Chan  JF, Yuan  S, Kok  KH, To  KK, Chu  H, Yang  J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395:514–23. DOIPubMedGoogle Scholar
  5. Wang  D, Hu  B, Hu  C, Zhu  F, Liu  X, Zhang  J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323:1061. DOIPubMedGoogle Scholar
  6. Department of Disease Control. Thailand. Guidelines for medical practice, diagnosis, treatment and prevention of healthcare-associated infection in response to patients with COVID-19 infection, revised version dated 16 February 2020 [cited 2020 Feb 21]. https://ddc.moph.go.th/viralpneumonia/eng/file/guidelines/G_CPG_en.pdf
  7. Prachayangprecha  S, Vichaiwattana  P, Korkong  S, Felber  JA, Poovorawan  Y. Influenza activity in Thailand and occurrence in different climates. Springerplus. 2015;4:356. DOIPubMedGoogle Scholar
  8. Department of Disease Control, Ministry of Public Health, Thailand. Novel coronavirus 2019 pneumonia situation: Thailand situation update on 15 February 2020 [cited 2020 Feb 16] https://ddc.moph.go.th/viralpneumonia/eng/file/situation/situation-no43-150263.pdf
  9. Zou  L, Ruan  F, Huang  M, Liang  L, Huang  H, Hong  Z, et al. SARS-Cov-2 viral load in upper respiratory specimens of infected patients. N Engl J Med. 2020;382:1177–9. DOIPubMedGoogle Scholar
  10. Bai  Y, Yao  L, Wei  T, Tian  F, Jin  DY, Chen  L, et al. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020; Epub ahead of print. DOIPubMedGoogle Scholar
  11. Zhang  W, Du  RH, Li  B, Zheng  X-S, Yang  X-L, Hu  B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect. 2020;9:386–9. DOIPubMedGoogle Scholar
  12. Yu  P, Zhu  J, Zhang  Z, Han  Y, Huang  L. A familial cluster of infection associated with the 2019 novel coronavirus indicating potential person-to-person transmission during the incubation period. J Infect Dis. 2020;jiaa077; Epub ahead of print. DOIPubMedGoogle Scholar
  13. Chen  N, Zhou  M, Dong  X, Qu  J, Gong  F, Han  Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395:507–13. DOIPubMedGoogle Scholar

Main Article

Page created: April 08, 2020
Page updated: June 18, 2020
Page reviewed: June 18, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external